Geron Corporation Presents RYTELO Clinical Data at ASH Meeting
1 report, 1 independent
Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Geron Corporation announced that six abstracts have been accepted for poster presentation at the 68th American Society of Hematology Annual Meeting. These presentations include new analyses regarding the clinical activity and approved dosing regimen of RYTELO (imetelstat) in lower-risk myelodysplastic syndromes. The company stated the presented information supports the scientific rationale for its approved dosing regimen.
From manilatimes.net
Why it matters
The presentation of clinical information on RYTELO relates to the drug's commercial viability and its standing within the hematology market. Geron Corporation is subject to the regulatory oversight and approval processes of the FDA.
From manilatimes.net
Who's involved
- Geron CorporationHematology-focused biopharmaceutical company presenting clinical data on RYTELO.
- American Society of HematologyOrganization hosting the annual meeting where Geron Corporation presents scientific data.
- NasdaqStock exchange where Geron Corporation is publicly listed.
- FDARegulatory body overseeing Geron Corporation's drug approval processes.